1921
Volume 75, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Some have claimed that triclabendazole, a safe and efficacious drug for the treatment of fascioliasis, also exhibits antischistosomal properties, but results are conflicting. We assessed the effect of triclabendazole and its two main metabolites against two different strains of harbored in mice. Low worm burden reductions (18.6–35.9%) were observed in mice infected with an Egyptian strain of and treated with a single dose of 120 mg/kg 3 days before infection or single/double doses of 120–200 mg/kg 7 weeks after infection. Triclabendazole failed to significantly reduce hepatic and intestinal tissue egg loads, and eggs of all developmental stages were observed. Administration of 400 mg/kg of either triclabendazole, triclabendazole sulphone, or triclabendazole sulfphoxide to mice infected with a Liberian strain of resulted in worm burden reductions < 10%. In comparison, high worm burden reductions (82–100%) were observed in –infected mice treated with single oral doses of 400, 500, or 500 mg/kg twice a day praziquantel, regardless of the strain. We conclude that triclabendazole and its main metabolites display weak and inconsistent schistosomicidal activities.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.2006.75.287
2006-08-01
2018-12-19
Loading full text...

Full text loading...

/deliver/fulltext/14761645/75/2/0750287.html?itemId=/content/journals/10.4269/ajtmh.2006.75.287&mimeType=html&fmt=ahah

References

  1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J, 2006. Schistosomiasis and water resources development: systematic review, meta-analysis and estimates of people at risk. Lancet Infect Dis 6 : 411–425. [Google Scholar]
  2. van der Werf MJ, de Vlas SJ, Brooker S, Looman CWN, Nagelkerke NJD, Habbema JDF, Engels D, 2003. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 86 : 125–139. [Google Scholar]
  3. Utzinger J, Keiser J, 2004. Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin Pharmacother 5 : 263–285. [Google Scholar]
  4. King CH, Dickman K, Tisch DJ, 2005. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 365 : 1561–1569. [Google Scholar]
  5. Engels D, Chitsulo L, Montresor A, Savioli L, 2002. The global epidemiological situation of schistosomiasis and new approaches to control and research. Acta Trop 82 : 139–146. [Google Scholar]
  6. WHO, 2002. Prevention and Control of Schistosomiasis and Soil-Transmitted Helminthiasis: Report of a WHO Expert Committee. Geneva: World Health Organization.
  7. Seubert J, Pohlke R, Loebich F, 1977. Synthesis and properties of praziquantel, a novel broad spectrum anthelmintic with excellent activity against schistosomes and cestodes. Experientia 33 : 1036–1037. [Google Scholar]
  8. Chen MG, 2005. Use of praziquantel for clinical treatment and morbidity control of schistosomiasis japonica in China: a review of 30 years’ experience. Acta Trop 96 : 168–176. [Google Scholar]
  9. Fenwick A, Savioli L, Engels D, Bergquist NR, Todd MH, 2003. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 19 : 509–515. [Google Scholar]
  10. Cioli D, 2000. Praziquantel: is there real resistance and are there alternatives? Curr Opin Infect Dis 13 : 659–663. [Google Scholar]
  11. Danso-Appiah A, de Vlas SJ, 2002. Interpreting low praziquantel cure rates of Schistosoma mansoni infections in Senegal. Trends Parasitol 18 : 125–129. [Google Scholar]
  12. Cioli D, Pica-Mattoccia L, 2003. Praziquantel. Parasitol Res 90 (suppl 1): S3–S9. [Google Scholar]
  13. Keiser J, Engels D, Büscher G, Utzinger J, 2005. Triclabendazole for the treatment of fascioliasis and paragonimiasis. Expert Opin Invest Drugs 14 : 1513–1526. [Google Scholar]
  14. El Sayed MH, Allam AF, 1997. Effect of triclabendazole on the tegument of Schistosoma mansoni: a scanning electron microscopic study. J Egypt Soc Parasitol 27 : 143–152. [Google Scholar]
  15. Khalil SS, 2000. On the schistosomicidal effect of triclabendazole: an experimental study. J Egypt Soc Parasitol 30 : 799–808. [Google Scholar]
  16. Coles GC, 1986. Anthelmintic activity of triclabendazole. J Helminthol 60 : 210–212. [Google Scholar]
  17. TDR, 2005. Seventeenth Programme Report (Progress 2003–2004): Making Health Research Work for Poor People. Geneva: Tropical Disease Research.
  18. Duvall RH, DeWitt WB, 1967. An improved perfusion technique for recovering adult schistosomes from laboratory animals. Am J Trop Med Hyg 16 : 483–486. [Google Scholar]
  19. Pellegrino J, Oliveira CA, Faria J, Cunha AS, 1962. New approach to the screening of drugs in experimental schistosomiasis mansoni in mice. Am J Trop Med Hyg 11 : 201–215. [Google Scholar]
  20. Kloetzel K, 1967. A suggestion for the prevention of severe clinical forms of schistosomiasis mansoni. Bull World Health Organ 37 : 686–687. [Google Scholar]
  21. Soliman GN, el Assal FM, Mansour NS, Garo K, 1986. Comparison of two Egyptian strains of Schistosoma mansoni in hamsters. Z Parasitenkd 72 : 353–363. [Google Scholar]
  22. el Mansoury ST, Bayoumi DM, 1995. Pathologic and ultrastructure characterization of two different strains of Schistosoma mansoni. J Egypt Soc Parasitol 25 : 1–10. [Google Scholar]
  23. World Health Organization, 1993. Evaluation of Certain Veterinary Drug Residues in Food. Geneva: World Health Organization.
  24. Manhaes-Rocha DA, Conte FP, Fidalgo-Neto AA, De-Oliveira AC, Ribeiro-Pinto LF, Paumgartten FJ, 2005. Alterations of hepatic microsomal enzymes in the early phase of murine schistosomiasis. Acta Trop 95 : 58–66. [Google Scholar]
  25. Maffei Facino R, Carini M, 1982. Loss of substrate binding capacity of the hepatic microsomal cytochrome P-450 in Fasciola hepatica infected rats: toxicological implications. Farmaco [Sci] 37 : 184–191. [Google Scholar]
  26. Sheir Z, Nasr AA, Massoud A, Salama O, Badra GA, El-Shennawy H, Hassan N, Hammad SM, 2001. A safe, effective, herbal antischistosomal therapy derived from myrrh. Am J Trop Med Hyg 65 : 700–704. [Google Scholar]
  27. Abo-Madyan AA, Morsy TA, Motawea SM, 2004. Efficacy of myrrh in the treatment of schistosomiasis (haematobium and mansoni) in Ezbet El-Bakly, Tamyia Center, El-Fayoum Governorate, Egypt. J Egypt Soc Parasitol 34 : 423–446. [Google Scholar]
  28. Botros S, William S, Ebeid F, Cioli D, Katz N, Day TA, Bennett JL, 2004. Lack of evidence for an antischistosomal activity of myrrh in experimental animals. Am J Trop Med Hyg 71 : 206–210. [Google Scholar]
  29. Barakat R, Elmorshedy H, Fenwick A, 2005. Efficacy of myrrh in the treatment of human schistosomiasis mansoni. Am J Trop Med Hyg 73 : 365–367. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2006.75.287
Loading
/content/journals/10.4269/ajtmh.2006.75.287
Loading

Data & Media loading...

  • Received : 23 Jan 2006
  • Accepted : 01 Apr 2006

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error